✓ You're confirmed. Your access to the MedTech IP Licensing workshop replay is ready below.
MedTech IP Licensing Workshop Replay
Watch the full session below. As you do, consider which of your medical technology assets could generate royalty income through the right licensing partner — without building a commercial operation from scratch.
Licensing is one of the safest, most effective ways to commercialize your MedTech IP — without building a company from scratch.
MedTech IP Basics
Patents, trademarks, trade secrets, and know-how — what each type is, how to protect it, and how each performs differently in a licensing negotiation.
Smart IP Licensing Campaign Strategy
How to create, organize, and manage a MedTech licensing campaign — from identifying target licensees to structuring outreach through deal close.
The Licensing Process — Step by Step
A clear walkthrough of how a MedTech licensing deal moves from initial contact to signed agreement — including the stages most innovators never anticipate.
Finding & Qualifying the Right Partner
What to look for in a MedTech licensing partner — market position, clinical capability, regulatory experience, and financial strength — and how to qualify them.
Royalties & Maximizing IP Value
How royalty rates are set in MedTech, what factors drive value in licensing negotiations, and proven strategies for maximizing total economic return on your IP.
Live Q&A — Your IP, Your Questions
Real answers to questions from MedTech innovators and IP owners about their specific technologies, licensing situations, and commercialization challenges.
📝 As You Watch — Questions to Consider
Take inventory — patents, patent applications, trade secrets, proprietary processes, clinical data, and know-how. Each has different licensing value and should be evaluated separately before you approach potential partners.
Think about which established MedTech companies serve your target market — they may be your ideal licensing partner, not your competitor. Their existing infrastructure is what makes licensing more valuable than going direct.
Compare the capital, time, regulatory effort, and risk of going direct versus partnering with a company already operating in your target market. For most MedTech innovators, the comparison is decisive.
Early-stage, clinical-stage, and cleared technologies all command different licensing structures and royalty rates. Know where you stand before you negotiate — and watch for how the workshop addresses each stage.
Rand Brenner
Rand Brenner has structured and executed licensing programs across medical technology, consumer products, entertainment, and regulated industries. He has developed licensing programs for properties including Mighty Morphin Power Rangers and Batman, and consults IP owners across the healthcare sector on licensing strategy and campaign management. Author of Hidden Wealth: The Money Making Power of Licensing (2019).